How JNJ’s Hypertension Segment Performed in 4Q17
By Daniel CollinsUpdated
Pulmonary Hypertension’s revenue trends
Johnson & Johnson (JNJ) established its Pulmonary Hypertension segment by the acquisition of Actelion Ltd in June 2017. In 4Q17, Johnson & Johnson’s (JNJ) Pulmonary Hypertension portfolio reported revenues of $610.0 million. In 4Q17, in the US market and the international markets, JNJ’s Pulmonary Hypertension segment generated revenues of $365.0 million and $245.0 million, respectively, which reflected an ~9.0% quarter-over-quarter decline.
In fiscal 2017, JNJ’s Pulmonary Hypertension segment reported net revenues of $1.3 billion. In 2017, in the US market and international markets, JNJ’s pulmonary hypertension drugs generated revenues of $773.0 million and $554.0 million, respectively.
Opsumit’s revenue trends
In 4Q17, JNJ’s Opsumit generated revenues of $269.0 million, which is ~4.0% growth on a quarter-over-quarter basis. In 4Q17, in the US and international markets, Opsumit reported revenues of $146.0 million and $123.0 million, respectively.
In fiscal 2017, Opsumit reported revenues of $573.0 million. In 2017, in the US market and international markets, Opsumit generated revenues of $320.0 million and $253.0 million, respectively.
Tracleer’s revenue trends
In 4Q17, Tracleer generated revenues of $167.0 million, which is an ~20.0% decline on a YoY basis. In 4Q17, in the US and international markets, Tracleer generated revenues of $76.0 million and $91.0 million, respectively.
In fiscal 2017, Tracleer reported revenues of $403.0 million, including $161.0 million and $242.0 million from the US and international markets, respectively.
Uptravi’s revenue trends
In 4Q17, Uptravi generated revenues of $130.0 million, which is ~5.0% growth on a quarter-over-quarter basis. In 4Q17, in the US and international markets, Uptravi reported revenues of $117.0 million and $13.0 million, respectively.
In 2017, Uptravi generated revenues of $236.0 million. In 2017, in the US and international markets, Uptravi generated revenues of $238.0 million and $25.0 million, respectively.
Some important drugs in the PAH market include Gilead Sciences’ (GILD) Letairis, Pfizer’s (PFE) Norvasc, United Therapeutics’ (UTHR) Remodulin, Orenitram, and Tyvaso, and Bayer’s (BAYZF) Adempas.
